Hepalys to develop Inventiva’s NASH treatment; Everest licenses Kezar’s autoimmune drug
Hepalys Pharma said Thursday it will develop and commercialize Inventiva’s nonalcoholic steatohepatitis (NASH) treatment in Japan and South Korea, paying $10 million upfront and up to $231 million in milestones as well as royalties.
The drug, lanifibranor, is currently in a Phase III trial.
Everest Medicines licenses Kezar’s autoimmune drug in China and other regions in Asia
China-based Everest Medicines is licensing Kezar Life Sciences’ zetomipzomib, which is being tested as a treatment for lupus nephritis, in Greater China, South Korea, and some Southeast Asian countries.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.